3 results
Primary Objective* To evaluate the antitumor efficacy of PO single agent CO-1686, as measured by ORR, when administered to patients with EGFR mutated, centrally confirmed T790M positive and T790M negative advanced NSCLC after tumor progression on 1…
Primary:To estimate the treatment effect of emactuzumab on objective response rate (ORR) by 6 months from initiation of therapy in the blinded phase compared to placeboSecondary:the effect of emactuzumab on clinical outcome assessments (COAs) for:o…
Aim of the study is to ascertain the order of magnitude to which ESWT may improve the performance of specific activities of daily living (ADL), measured by Goal Entertainment Scaling (GAS) in people with spinal cord injury and spasticity in the…